当前位置:
X-MOL 学术
›
Blood Cancer J.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
Blood Cancer Journal ( IF 12.8 ) Pub Date : 2024-03-19 , DOI: 10.1038/s41408-024-01028-4 Ayalew Tefferi , Animesh Pardanani , Kebede H. Begna , Aref Al-Kali , William J. Hogan , Mark R. Litzow , Rhett P. Ketterling , Kaaren K. Reichard , Naseema Gangat
中文翻译:
骨髓纤维化中的 Calr 1 型/样突变是莫莫替尼药物存活率和无移植寿命的最重要预测因子
更新日期:2024-03-20
Blood Cancer Journal ( IF 12.8 ) Pub Date : 2024-03-19 , DOI: 10.1038/s41408-024-01028-4 Ayalew Tefferi , Animesh Pardanani , Kebede H. Begna , Aref Al-Kali , William J. Hogan , Mark R. Litzow , Rhett P. Ketterling , Kaaren K. Reichard , Naseema Gangat
中文翻译:
骨髓纤维化中的 Calr 1 型/样突变是莫莫替尼药物存活率和无移植寿命的最重要预测因子